Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis

Arthritis and Rheumatology

Volumn 66, Issue 9, 2014, Pages 2590-2600

  Glaesener, Stephanie ^a,b   Quách, Tâm D ^a,b   Onken, Nils ^c   Weller Heinemann, Frank ^c   Dressler, Frank ^b   Huppertz, Hans Iko ^c   Thon, Angelika ^b   Meyer Bahlburg, Almut ^b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Prof Hess Children's Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ARTICLE; B LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLICULAR HELPER T CELL; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; JUVENILE RHEUMATOID ARTHRITIS; MALE; PRIORITY JOURNAL;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; B-LYMPHOCYTES; CHILD; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84907381004     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38736     Document Type: Article

References (50)

1. Wiegering V, Girschick HJ, Morbach H. B-cell pathology in juvenile idiopathic arthritis. Arthritis 2010;2010:759868.
2. Gattorno M, Prigione I, Morandi F, Gregorio A, Chiesa S, Ferlito F, et al. Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. Arthritis Res Ther 2005;7:R256-67.
3. Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 2011;10:482-9.
4. Omoyinmi E, Hamaoui R, Pesenacker A, Nistala K, Moncrieffe H, Ursu S, et al. Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2012;51:1881-6.
5. Prakken BJ, Albani S. Using biology of disease to understand and guide therapy of JIA. Best Pract Res Clin Rheumatol 2009;23:599-608.
6. Sweet RA, Lee SK, Vinuesa CG. Developing connections amongst key cytokines and dysregulated germinal centers in autoimmunity. Curr Opin Immunol 2012;24:658-64.
7. Alexeeva EI, Valieva SI, Bzarova TM, Semikina EL, Isaeva KB, Lisitsyn AO, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011;30:1163-72.
8. Braun-Moscovici Y, Butbul-Aviel Y, Guralnik L, Toledano K, Markovits D, Rozin A, et al. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatol Int 2013;33:1495-504.
9. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009;11:R131.
10. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005;201:1659-67. (Pubitemid 40721009)
11. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84. (Pubitemid 41407360)
12. Mello SB, Tavares ER, Bulgarelli A, Bonfa E, Maranhao RC. Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis. Int J Nanomedicine 2013;8:443-9.
13. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93. (Pubitemid 32162981)
14. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9. (Pubitemid 30151920)
15. Apostolaki M, Armaka M, Victoratos P, Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 2010;11:1-26.
16. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, et al. Anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008;180:688-92.
17. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009;11:R84.
18. Vinay DS, Kwon BS. Targeting TNF superfamily members for therapeutic intervention in rheumatoid arthritis. Cytokine 2012;57:305-12.
19. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
20. Rowland SL, Leahy KF, Halverson R, Torres RM, Pelanda R. BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol 2010;185:4570-81.
21. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-4. (Pubitemid 32848063)
22. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007;19:327-36. (Pubitemid 46687013)
23. Craft JE. Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol 2012;8:337-47.
24. Ma J, Zhu C, Ma B, Tian J, Baidoo SE, Mao C, et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol 2012;2012:827480.
25. Wallace CA, Ruperto N, Giannini E, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology International Trials Organization, and the Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
26. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
27. Meyer-Bahlburg A, Andrews SF, Yu KO, Porcelli SA, Rawlings DJ. Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J Exp Med 2008;205:155-68. (Pubitemid 351185723)
28. Bohm I. Decrease of B-cells and autoantibodies after low-dose methotrexate. Biomed Pharmacother 2003;57:278-81. (Pubitemid 37123098)
29. Wascher TC, Hermann J, Brezinschek HP, Brezinschek R, Wilders-Truschnig M, Rainer F, et al. Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis. Clin Investig 1994;72:535-40. (Pubitemid 24253421)
30. Stamp LK, Hazlett J, Roberts RL, Frampton C, Highton J, Hessian PA. Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther 2012;14:R138.
31. Rackham OJ, Sills JA, Davidson JE. Immunoglobulin levels in methotrexate treated paediatric rheumatology patients. Arch Dis Child 2002;87:147-8. (Pubitemid 34828023)
32. Tussiwand R, Bosco N, Ceredig R, Rolink AG. Tolerance checkpoints in B-cell development: Johnny B good. Eur J Immunol 2009;39:2317-24.
33. Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, et al. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis 2010;69:1479-83.
34. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012;71:1914-5.
35. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol 2013;32:1429-35.
36. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9. (Pubitemid 32537529)
37. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109:59-68. (Pubitemid 34052542)
38. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10. (Pubitemid 32038409)
39. Gheita TA, Bassyouni IH, Emad Y, el-Din AM, Abdel-Rasheed E, Hussein H. Elevated BAFF (BLyS) and APRIL in Juvenile idiopathic arthritis patients: relation to clinical manifestations and disease activity. Joint Bone Spine 2012;79:285-90.
40. Hong SD, Reiff A, Yang HT, Migone TS, Ward CD, Marzan K, et al. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum 2009;60:3400-9.
41. Alsaleh G, Messer L, Semaan N, Boulanger N, Gottenberg JE, Sibilia J, et al. BAFF synthesis by rheumatoid synoviocytes is positively controlled by α5β1 integrin stimulation and is negatively regulated by tumor necrosis factor α and Toll-like receptor ligands. Arthritis Rheum 2007;56:3202-14. (Pubitemid 47585415)
42. Lee GH, Lee J, Lee JW, Choi WS, Moon EY. B cell activating factor-dependent expression of vascular endothelial growth factor in MH7A human synoviocytes stimulated with tumor necrosis factor-α. Int Immunopharmacol 2013;17:142-7.
43. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005;174:864-70. (Pubitemid 40094281)
44. Assi LK, Wong SH, Ludwig A, Raza K, Gordon C, Salmon M, et al. Tumor necrosis factor α activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum 2007;56:1776-86. (Pubitemid 47110377)
45. La DT, Collins CE, Yang HT, Migone TS, Stohl W. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor a antagonists: differential effects between good and poor clinical responders. Ann Rheum Dis 2008;67:1132-8.
46. Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study. J Rheumatol 2013;40:579-89.
47. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity 2009;30:324-35.
48. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly-TFH cells in human health and disease. Nat Rev Immunol 2013;13:412-26.
49. Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010;62:234-44.
50. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.